A randomized, double-blind controlled trial of interferon alpha-2b and ribavirin vs. interferon alpha-2b and amantadine for treatment of chronic hepatitis C non-responder to interferon monotherapy

Journal of Hepatology

Volumn 34, Issue 1, 2001, Pages 128-133

  Younossi, Zobair M ^a,d   Mullen, Kevin D ^b   Zakko, Wisam ^a   Hodnick, Sandra ^a   Brand, Edward ^c   Barnes, David S ^a   Carey, William D ^a   McCullough, Arthur C ^b   Easley, Kirk ^a   Boparai, Navdeep ^a   Gramlich, Terry ^a  

^a LERNER RESEARCH INSTITUTE   (United States)

^b CASE WESTERN RESERVE UNIVERSITY   (United States)

^c Cleveland HCV Consortium   (United States)

^d INOVA FAIRFAX HOSPITAL   (United States)

Author keywords

Amantadine; Hepatitis C; Interferon non responders

Indexed keywords

ALANINE AMINOTRANSFERASE; ALPHA INTERFERON; ALPHA2B INTERFERON; AMANTADINE; ANTIVIRUS AGENT; RECOMBINANT ALPHA2A INTERFERON; RECOMBINANT ALPHA2B INTERFERON; RIBAVIRIN; VIRUS RNA;

ANEMIA; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG INDUCED DISEASE; DRUG RESISTANCE; FEMALE; HEPATITIS C; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; MYALGIA; PRIORITY JOURNAL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; RELAPSE; RETREATMENT; SPEECH DISORDER; TREATMENT OUTCOME; VIRUS HEPATITIS;

ADULT; AGED; AMANTADINE; ANTIVIRAL AGENTS; DOUBLE-BLIND METHOD; DRUG THERAPY, COMBINATION; FEMALE; HEMOGLOBINS; HEPATITIS C, CHRONIC; HUMANS; INTERFERON ALFA-2B; MALE; MIDDLE AGED; QUALITY OF LIFE; RIBAVIRIN; THYROTROPIN;

EID: 0035133667     PISSN: 01688278     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0168-8278(00)00003-9     Document Type: Article

References (28)

1. The prevalence of hepatitis C virus infection in the United States 1988 through 1994
2. An update on hepatitis C: The silent epidemic
3. Chronic hepatitis C: A clinical overview
4. Recommendations for the prevention and control of hepatitis C virus (HCV) infection and HCV-related chronic liver disease
5. Hepatitis C: The clinical spectrum of disease
6. The natural history of chronic hepatitis C virus infection
7. The long-term pathological evolution of chronic hepatitis C
8. The roles of amantadine, rimantadine, ursodeoxycholic acid and NSAIDs alone or in combination with alpha interferon in the treatment of chronic hepatitis C
9. Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C
10. Treatment of chronic hepatitis C with recombinant interferon alfa. A multicenter randomized, controlled trial
11. Standards of treatment in chronic hepatitis C
12. A Pilot study of combination therapy with ribavirin plus interferonalpha for interferon-alpha resistant chronic hepatitis C
13. Combination treatment with interferon alfa-2b and ribavirin for chronic hepatitis C in patients who have failed to achieve sustained response to interferon alone: Swedish experience
14. Interferon and ribavirin versus interferon and amantadine in interferon non-responders with hepatitis C
15. Histopathology of hepatitis C virus infection
16. Development of a disease-specific health-related quality of life index for chronic liver disease
17. Economic and quality of life outcomes in viral hepatitis
18. Chronic hepatitis C: Current disease management
19. The treatment of chronic viral hepatitis
20. Ten-year follow-up after interferon-alpha therapy for chronic hepatitis C
21. Long-term histologic improvement and loss of detectable intrahepatic HCV RNA in patients with chronic hepatitis C and sustained response to interferon-alpha therapy
22. Reduction of health-related quality of life in chronic hepatitis C and improvement with interferon therapy
23. Cost effectiveness of interferon α-2b combined with ribavirin for the treatment of chronic hepatitis C
24. Is 'a la carte' combination interferon alpha-2b plus ribavirin regimen possible for the first line treatment in patients with chronic hepatitis?
25. Reduction of quality of life in patients infected with HCV
26. Safety of combination of interferon alpha-2b/ribavirin therapy in chronic hepatitis C-relapsed and treatment naive patients
27. Treatment strategies for hepatitis C: Making the best of limited options